Clinical Trials

YCAAD has been involved in a host of both industry and investigator sponsored trials.  Below is a list of the most recent studies patients at YCAAD have been part of. 

Open to Enrollment

  • National Institute of Health (NIH) - Mechanisms and Mediators of Lung Disease .
  • Asthma

  • NAVIGATOR: Study to Evaluate Tezepelumab in Adults & Adolescents with Severe Uncontrolled Asthma
    ClinicalTrials.gov Identifier: NCT03347279
    *Notes: Sponsored clinical trial for patients with Severe Uncontrolled Asthma. Specific inclusion and exclusion criteria apply.
  • PREPARE STUDY: Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations: PeRson EmPowered Asthma Relief
    ClinicalTrials.gov Identifier: NCT02995733
    *Notes: National Institute of Health sponsored study focused on Hispanic/Latino and African American people. Specific inclusion and exclusion criteria apply. The informed consent process and the conduction of the study could be on ENGLISH or SPANISH.


  • GlaxoSmithKline - A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome (CUPS); HIC#: 0810004339
  • Genentech - A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects fo Lebrikizumab on Airway Eosinophilic Inflammation in Patients with Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication (CLAVIER); HIC#: 1311013055

    COPD

  • AstraZeneca - A Randomized, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (GALATHEA); HIC#: 1503015478

Active But Closed to Enrollment

  • Asthma

  • Genentech - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma who are on Inhaled Corticosteroids and a Second Controller Medication (LAVOLTA); HIC#: 1311013055
  • AstraZeneca - A Multicentre-Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroids Plus Long-acting beta2 Agonist in Patients with Uncontrolled Asthma (SIROCCO); HIC#: 1409014573
  • GlaxoSmithKline - A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma; HIC#: 1410014775
  • GlaxoSmithKline - A Multi-Centre, Open-Label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects; HIC#: 1208010732

To be open soon

  • Asthma

  • CHRONICLE: Observational Study of Characteristics, Treatment and Outcomes with Severe Asthma in the United States
    ClinicalTrials.gov Identifier: NCT0337304
    *Notes: Observational and in-interventional study open to population with severe asthma. Specific inclusion and exclusion criteria apply. The informed consent process and the conduction of the study could be on ENGLISH or SPANISH.
  • MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler(BDA MDI/PT027) in Adults and Children 4 Years of Age or Older with Asthma
    ClinicalTrials.gov Identifier: NCT03769090
    *Notes: more information regarding this clinical trail will be posted.

COPD

  • To be announced
Clinical Trials

caption default